Phaseline

Companies › Bexion Pharmaceuticals

Bexion Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BXQ-350
Saposin C (SapC) combined with phospholipid dioleoylphosphatidyl-serine (DOPS) forming a p
PSPhase 1Metastatic Colorectal CarcinomaNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05322590BXQ-350Phase 1Metastatic Colorectal CarcinomaOncologyNov 2026

Targets

PS (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.